Vivek Ramaswamy (Jeff Rumans/JPM 2020)

Vivek Ra­maswamy eyes an I/O vant with up to $2B li­cens­ing deal

Has Vivek Ra­maswamy found the seed of his next vant?

On Mon­day, Roivant an­nounced a rare part­ner­ship deal, sign­ing an agree­ment with the Ger­man im­muno-on­col­o­gy small-cap Af­fimed worth $60 mil­lion up­front and up to $2 bil­lion in mile­stones. For all the com­pa­ny’s sprawl­ing ten­ta­cles, it’s the first time since their 2018 pact with Dai­ichi Sankyo that Roivant it­self has an­nounced a li­cens­ing agree­ment with an­oth­er de­vel­op­er and one of the largest deals, in terms of biobucks, they’ve ever dis­closed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.